Insights on the evidence of immunotherapy in hereditary cancers from 2nd edition of the National Cancer Centre Singapore’s Grand Rounds
The National Cancer Centre Singapore (NCCS) recently held the 2nd edition of its Medical Grand Rounds, a platform designed to foster discussions and debates on the latest advancements in oncology.
The Grand Rounds are modeled after traditional academic medical rounds, where complex clinical cases, innovative treatments, and new research findings are presented. The goal is to inspire clinicians and researchers to push the boundaries of current knowledge and improve patient care.
A highlight of the event was a debate between two prominent figures in the oncology field. The discussion revolved around the progress in cancer treatments, with particular focus on comparing advancements in breast cancer and lung cancer therapies. Such debates are intended to spark innovative ideas and discussions that can lead to significant strides in cancer treatment and care.
The National Cancer Centre Singapore (NCCS) shared on LinkedIn:
“‘Are more young people getting cancer?” This was the hot topic presented by a panel of multidisciplinary experts at the 2nd edition of the National Cancer Centre Singapore’s Grand Rounds held earlier this evening.
The Rounds began with a compelling presentation of a young patient’s case by Dr Cai Mingzhe from the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, SGH and NCCS, which was followed by Ms Diana Ishak from NCCS’ Cancer Genetics Service, who provided a thorough overview of Lynch Syndrome.
Special guest Clin Assoc Prof Herbert Loong, Deputy Medical Director of the Phase 1 Clinical Trials Centre at The Chinese University of Hong Kong, shed light on the role of immunotherapy in hereditary cancers after which Clin Asst Prof Eileen Poon, Medical Lead for Adolescent and Young Adult Oncology at NCCS closed the programme with a deep dive into common adolescent and young cancers in Asia.
The Grand Rounds gave the audience, made up of oncologists, researchers and allied health professionals from across Singapore, a unique opportunity to come together and learn from experts who treat young patients, and acquire knowledge to help them better support this group of patients and their unique needs.”
Herbert Loong added a comment:
“Kudos to Claramae Chia, Han Chong Toh and Rebecca Dent for putting this 2nd National Cancer Centre Singapore Grand Rounds together! A pleasure to have been invited and to share some insights on the evidence of immunotherapy in hereditary cancers, specifically in dMMR/MSI-H disease. Very informative multidisciplinary discussions with interests from multiple stakeholders. Together we can help move the field further forward.”
Claramae Chia also added:
“Had an insightful grand round session and learned new things yesterday. Kudos to the speakers Eileen Poon, Joanne Ngeow, Herbert Loong, Yong Tze Tein and Chang Meihuan for their excellent talks and all the participants to for the lively discussion. And of course to Rebecca Dent and Han Chong Toh for starting and continuing this initiative where we can bring our people together to keep learning from each other.”
Source: The National Cancer Centre Singapore (NCCS)/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023